Clinical Trial Update: Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)

View source ↗

Summary

Real-world data from a completed clinical trial program examining durvalumab after chemoradiotherapy in Asian stage III non-small cell lung cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Status: COMPLETED